指南与共识放疗物理与技术

儿童恶性肿瘤的质子治疗:事实、数据与成本。PTCOG儿科小组委员会、PROS与EPTN的联合共识声明

Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN.
指南 / 共识 · Radiother Oncol · 2018-06-21

该联合共识声明评估了儿童肿瘤质子治疗的现有数据,指出质子治疗在降低非靶结构辐射剂量方面具有明确优势,但成本高于常规放疗;文中讨论了高质量数据开发的紧迫性、质子与全身药物联合的优势及已发表的成本效果数据。

要点

  • 质子治疗降低非靶结构辐射剂量,具有明确优势,但成本高于常规放疗。
  • 需开发高质量数据以支持儿童质子治疗的临床决策。
  • 已汇总质子联合全身药物及成本效果数据。

核心结论

  • 质子治疗在儿童肿瘤中具有降低非靶结构辐射剂量的明确优势,但成本高于常规放疗,可能给医疗系统带来财务压力并产生社会影响。

研究设计与样本

  • 由PTCOG儿科小组委员会、PROS与EPTN联合制定的共识声明,基于现有已发表数据评估儿童肿瘤质子治疗。

主要发现

  • 质子治疗降低非靶结构/体积的辐射「浴」剂量,同时以杀肿瘤剂量最佳覆盖肿瘤。
  • 质子治疗相比常规放疗有额外成本,可能对医疗系统造成财务压力并产生社会影响。

临床怎么用

  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiotherapy plays an important role in the management of childhood cancer, with the primary aim of achieving the highest likelihood of cure with the lowest risk of radiation-induced morbidity. Proton therapy (PT) provides an undisputable advantage by reducing the radiation 'bath' dose delivered to non-target structures/volume while optimally covering the tumor with tumoricidal dose. This treatment modality comes, however, with an additional costs compared to conventional radiotherapy that could put substantial financial pressure to the health care systems with societal implications. In this review we assess the data available to the oncology community of PT delivered to children with cancer, discuss on the urgency to develop high-quality data. Additionally, we look at the advantage of combining systemic agents with protons and look at the cost-effectiveness data published so far.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Weber DC, Habrand JL, Hoppe BS, et al. Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN. Radiother Oncol. 2018. PMID: 29937209. doi:10.1016/j.radonc.2018.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。